CHMP ADOPTED EXTENSION TO EXISTING INDICATION TO EXTEND USE OF ABRYSVO TO ADULTS FROM 18 YEARS OF AGE
Source text: [ID:]
Further company coverage: PFE.N
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.